June 30, 2017 / 5:38 PM / 22 days ago

BRIEF-Theratechnologies says FDA sets PDUFA date of Jan 3 for ibalizumab application

1 Min Read

June 30 (Reuters) - Theratechnologies Inc:

* FDA grants priority review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab

* FDA has set a prescription drug user fee act target action date of January 3, 2018, for ibalizumab application Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below